Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Institute (NCI)
OBJECTIVES:
I. Determine the response rate to oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma.
II. Determine the treatment-related toxicity of this drug in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to histologic subtype (indolent vs aggressive).
Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A maximum of 72 patients will be accrued for this study within 2-3 years.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype
* Indolent
* Follicular small cleaved cell
* Follicular mixed cell
* Small lymphocytic
* Mucosa-associated lymphoid tissue (MALT)
* Monocytoid B-cell
* Waldenstrom's macroglobulinemia
* Aggressive
* Follicular large cell
* Diffuse large cell
* Immunoblastic
* Mantle cell
* Ki-1+ NHL
* Peripheral T-cell
* Angiocentric and angioimmunoblastic
* Transformed lymphoma
Bidimensionally measurable disease
No more than 3 prior treatment regimens as follows:
* Primary radiotherapy is 1 regimen
* Combined therapy with radiotherapy and chemotherapy is 1 regimen
* Alternating therapy is 1 regimen
No known brain metastases
Performance status - ECOG 0-2
Performance status - Karnofsky 50-100%
WBC count at least 3,000/mm\^3
Absolute neutrophil count at least 1,500/mm\^3
Platelet count at least 100,000/mm\^3
Bilirubin normal
SGOT/SGPT no greater than 2.5 times upper limit of normal
Creatinine normal
Creatinine clearance at least 60 mL/min
No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia
No neuropathy greater than grade 1
No history of allergy to platinum compounds or antiemetics
No uncontrolled illness
No active infection
Not pregnant or nursing
Fertile patients must use effective contraception
No concurrent colony-stimulating factors during first course of therapy
At least 4 weeks since prior chemotherapy
At least 4 weeks since prior radiotherapy
No other concurrent investigational drugs
No concurrent antiretroviral therapy for HIV-positive patients
Clareo Health | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
